NeuroSense Therapeutics annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
NeuroSense Therapeutics Stock-Based Compensation Growth & History (NRSN)
NeuroSense Therapeutics's stock-based compensation was $2.1M for fiscal 2025.
View full NeuroSense Therapeutics company overviewNeuroSense Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.1M | $1.6M | +284.20% |
| 2024 | 2024-12-31 | $557,000 | −$2.2M | −80.09% |
| 2023 | 2023-12-31 | $2.8M | −$2.3M | −45.19% |
| 2022 | 2022-12-31 | $5.1M | $3.3M | +176.10% |
| 2021 | 2021-12-31 | $1.8M | $1.6M | +619.46% |
| 2020 | 2020-12-31 | $257,000 | $120,000 | +87.59% |
| 2019 | 2019-12-31 | $137,000 | — | — |
NeuroSense Therapeutics stock-based compensation trends
Over the last five fiscal years, NeuroSense Therapeutics's stock-based compensation increased from $257,000 to $2.1M, a change of $1.9M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review NeuroSense Therapeutics source filings ↗